Area of research
Oncology · Pathology and Forensic Medicine
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Viral-associated cancers and disorders, Chronic Lymphocytic Leukemia Research, and CAR-T cell therapy research.
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
AIDS-Related Kaposi Sarcoma, Version 2.2019
Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016
Long-term survival in AIDS-related primary central nervous system lymphoma
Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial
AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015
A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
Non-Hodgkin’s Lymphomas, Version 4.2014
Non-Hodgkin’s Lymphomas, Version 2.2014
Association of early HIV viremia with mortality after HIV-associated lymphoma
Short Communication: Lack of Occult HIV Infection Among Non-AIDS-Defining Cancer Patients in Three Academic Oncology Clinics in the United States
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999–2008 and treated with curative intent in the AIDS Malignancy Consortium